Lv64
1660 积分 2022-04-26 加入
PL02.12 Ivonescimab vs Placebo Plus Chemo, Phase 3 in Patients with EGFR+ NSCLC Progressed with 3rd gen EGFR-TKI Treatment: HARMONi
29天前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
29天前
已完结
CD25: A potential tumor therapeutic target
1个月前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
1个月前
已完结
The present and future of bispecific antibodies for cancer therapy
1个月前
已完结
Tumor border sharpness correlates with HLA-G expression in low-grade gliomas
6个月前
已完结
HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma
6个月前
已完结
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors
7个月前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
8个月前
已完结
皖公网安备34019202002308
